Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Oncolytics Bio (ONC.TO)
Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 209,835
  • Shares Outstanding, K 73,369
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,835 K
  • 60-Month Beta 2.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.44
Trade ONC.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.44
  • Most Recent Earnings -0.12 on N/A
  • Next Earnings Date 11/06/23
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.72 +2.21%
on 09/19/23
3.31 -16.01%
on 09/06/23
-0.45 (-13.93%)
since 09/01/23
3-Month
2.58 +7.75%
on 08/14/23
4.45 -37.53%
on 07/11/23
-0.71 (-20.34%)
since 06/30/23
52-Week
1.48 +87.84%
on 04/11/23
4.49 -38.08%
on 06/23/23
+1.07 (+62.57%)
since 10/03/22

Most Recent Stories

More News
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

/PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in...

ONC.TO : 2.77 (-3.15%)
ONCY : 2.01 (-3.79%)
MRUS : 20.92 (-6.98%)
GH : 29.73 (+1.88%)
MDT : 76.63 (-1.47%)
NVDA : 438.34 (-2.12%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 26, 2023 – USA News Group  –  The seriousness of pancreatic cancer continues to grow, with increasing alarm since...

ONCY : 2.01 (-3.79%)
ONC.TO : 2.77 (-3.15%)
MRUS : 20.92 (-6.98%)
GH : 29.73 (+1.88%)
MDT : 76.63 (-1.47%)
NVDA : 438.34 (-2.12%)
Stocks in play: Oncolytics Biotech, Inc.

Says it has been named by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its second ...

ONC.TO : 2.77 (-3.15%)
Pancreatic Cancer's Alarming Surge in Young Adults Sparks Research into New Treatments

USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer...

ONCY : 2.01 (-3.79%)
ONC.TO : 2.77 (-3.15%)
MRUS : 20.92 (-6.98%)
GH : 29.73 (+1.88%)
MDT : 76.63 (-1.47%)
NVDA : 438.34 (-2.12%)
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END

BMY : 57.32 (-0.92%)
ONCY : 2.01 (-3.79%)
ONC.TO : 2.77 (-3.15%)
VACC : 3.30 (+2.80%)
BPTS : 1.0250 (-0.49%)
RNAZ : 0.4899 (+6.50%)
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid...

ONC.TO : 2.77 (-3.15%)
ONCY : 2.01 (-3.79%)
VACC : 3.30 (+2.80%)
BPTS : 1.0250 (-0.49%)
RNAZ : 0.4899 (+6.50%)
BMY : 57.32 (-0.92%)
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies   BOSTON, MA., San Diego, CA., and Calgary, AB. – September 26,...

ONCY : 2.01 (-3.79%)
ONC.TO : 2.77 (-3.15%)
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

/PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN)...

ONC.TO : 2.77 (-3.15%)
ONCY : 2.01 (-3.79%)
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

/CNW/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today...

ONCY : 2.01 (-3.79%)
ONC.TO : 2.77 (-3.15%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling...

RY : 82.61 (-2.58%)
RY.TO : 113.43 (-2.17%)
ONCY : 2.01 (-3.79%)
ONC.TO : 2.77 (-3.15%)
JAZZ : 127.11 (-0.49%)
ZYME : 6.12 (-1.13%)
AMGN : 261.39 (-1.85%)
PTGX : 16.35 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 3.16
2nd Resistance Point 3.09
1st Resistance Point 2.97
Last Price 2.77
1st Support Level 2.78
2nd Support Level 2.71
3rd Support Level 2.59

See More

52-Week High 4.49
Fibonacci 61.8% 3.34
Fibonacci 50% 2.98
Last Price 2.77
Fibonacci 38.2% 2.63
52-Week Low 1.48

See More

Business Summary

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar